Work

A Phase 2 Clinical Trial of AP23573, an mTOR Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies.

Year: 2005

Type: article

Source: Blood

DOI: 10.1182/blood.v106.11.2980.2980

Authors: David A. Rizzieri, Eric Feldman, Joseph O. Moore, Gail J. Roboz, John F. DiPersio, Nashat Gabrail, Wendy Stock, Victor M. Rivera, Maher Albitar, Camille L. Bedrosian, Francis Giles

Institutions: Duke Medical Center, Cornell University, Weill Cornell Medicine, Washington University Medical Center, Gabrail Cancer Center, University of Chicago, ARIAD Pharmaceuticals (United States), Quest Diagnostics (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2532819729

FWCI: 0.997

Cites:

Cited by: 13

Related to: 10